Longeveron Inc. (LGVN)

1.7800 -0.0100 (-0.56%) As of 10:20AM EDT. Market open.

Longeveron Inc.

Life Science & Technology Park
Suite 520 1951 NW 7th Avenue
Miami, FL 33136
United States
844 470 2550
https://longeveron.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 23

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Joshua Michael Hare FACC, M.D.	Co-Founder, Chief Science Officer & Chairman	74k	N/A	1963
Mr. Mohamed Wa'el Ahmed Hashad M.B.A.	CEO & Director	867.85k	N/A	1962
Ms. Lisa A. Locklear M.B.A.	CFO & Treasurer	472.27k	N/A	1961
Mr. Paul T. Lehr J.D.	International Executive Director, General Counsel & Secretary	554.05k	N/A	1968
Dr. Dan Gincel Ph.D.	Senior Vice President of Strategic Collaborations & Scientific Affairs	N/A	N/A	1971
Dr. Nataliya Agafonova M.D.	Chief Medical Officer	N/A	N/A	1969
Ms. Lisa McClain-Moss	Vice President of Manufacturing	N/A	N/A	1971
Mr. Brian G Rash Ph.D.	VP of Research & Discovery	N/A	N/A	N/A
Ms. Elly Ryu	VP & Corporate Controller	N/A	N/A	1981
Mr. Michael Mannarino	VP & Corporate Controller	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Corporate Governance

Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.